Luminex to Buy Back Shares | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Wednesday that its board of directors has authorized the purchase of up to 1 million shares of the firm's common stock, but not more than $21 million in aggregate purchase price.

Luminex said that the repurchase program will run through November 2011. The purchases will be made from time to time on the open market or through privately negotiated transactions. Luminex currently has 42.3 million shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.